Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects - Jenkins, H.; Sakurai, Y.; Nishimura, A.; Okamoto, H.; Hibberd, M.; Jenkins, R.; Yoneyama, T.; Ashida, K.; Ogama, Y.; Warrington, S. (Alimentary pharmacology & therapeutics, 2015)
Keywords: Adult; Asian Continental Ancestry Group; Dose-Response Relationship, Drug; Double-Blind Method; European Continental Ancestry Group; Gastric Acid; Gastrointestinal Agents - adverse effects; Gastrointestinal Agents - pharmacokinetics; Gastrointestinal Agents - pharmacology; Half-Life; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nervous System Diseases; Potassium - pharmacology; Pyrroles - adverse effects; Pyrroles - pharmacokinetics; Pyrroles - pharmacology; Randomised Clinical Trials; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Sulfonamides - pharmacology; United Kingdom; Young Adult